119 related articles for article (PubMed ID: 20472447)
1. Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Velankar AD; Quintini G; Prabhu A; Weber A; Hunaeus G; Voland B; Wuest M; Orjeda C; Harel D; Varghese S; Gore V; Patil M; Gayke D; Herdemann M; Heit I; Zaliani A
Bioorg Med Chem; 2010 Jun; 18(12):4547-59. PubMed ID: 20472447
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions.
Kaur M; Bahia MS; Silakari O
Eur J Pharm Sci; 2012 Oct; 47(3):574-88. PubMed ID: 22820564
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
5. Itk inhibitors: a patent review.
Lo HY
Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
[TBL] [Abstract][Full Text] [Related]
6. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
Norman P
Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
8. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
9. Optimisation of ITK inhibitors through successive iterative design cycles.
Herdemann M; Weber A; Jonveaux J; Schwoebel F; Stoeck M; Heit I
Bioorg Med Chem Lett; 2011 Mar; 21(6):1852-6. PubMed ID: 21316219
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
11. Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.
Burch JD; Lau K; Barker JJ; Brookfield F; Chen Y; Chen Y; Eigenbrot C; Ellebrandt C; Ismaili MH; Johnson A; Kordt D; MacKinnon CH; McEwan PA; Ortwine DF; Stein DB; Wang X; Winkler D; Yuen PW; Zhang Y; Zarrin AA; Pei Z
J Med Chem; 2014 Jul; 57(13):5714-27. PubMed ID: 24918870
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2-inducible T cell kinase regulates mast cell degranulation and acute allergic responses.
Forssell J; Sideras P; Eriksson C; Malm-Erjefält M; Rydell-Törmänen K; Ericsson PO; Erjefält JS
Am J Respir Cell Mol Biol; 2005 Jun; 32(6):511-20. PubMed ID: 15778496
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
[TBL] [Abstract][Full Text] [Related]
16. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
[TBL] [Abstract][Full Text] [Related]
17. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
[TBL] [Abstract][Full Text] [Related]
18. Identification of potent ITK inhibitors through focused compound library design including structural information.
Herdemann M; Heit I; Bosch FU; Quintini G; Scheipers C; Weber A
Bioorg Med Chem Lett; 2010 Dec; 20(23):6998-7003. PubMed ID: 20965724
[TBL] [Abstract][Full Text] [Related]
19. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
[TBL] [Abstract][Full Text] [Related]
20. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.
McLean LR; Zhang Y; Zaidi N; Bi X; Wang R; Dharanipragada R; Jurcak JG; Gillespy TA; Zhao Z; Musick KY; Choi YM; Barrague M; Peppard J; Smicker M; Duguid M; Parkar A; Fordham J; Kominos D
Bioorg Med Chem Lett; 2012 May; 22(9):3296-300. PubMed ID: 22464456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]